Sight Sciences Inc.

NASDAQ: SGHT · Real-Time Price · USD
4.20
0.00 (0.00%)
At close: Jun 06, 2025, 3:59 PM
4.20
0.00%
After-hours: Jun 06, 2025, 04:04 PM EDT

Company Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.

The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.

The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences Inc.
Sight Sciences Inc. logo
Country United States
IPO Date Jul 15, 2021
Industry Medical - Devices
Sector Healthcare
Employees 216
CEO Paul Badawi

Contact Details

Address:
4040 Campbell Avenue
Menlo Park, California
United States
Website https://www.sightsciences.com

Stock Details

Ticker Symbol SGHT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001531177
CUSIP Number 82657M105
ISIN Number US82657M1053
Employer ID 80-0625749
SIC Code 3841

Key Executives

Name Position
Paul Badawi Co-Founder, President, Chief Executive Officer & Director
Alison Perry Bauerlein Chief Financial Officer, Principal Financial & Accounting Officer and Treasurer
Dr. David Badawi M.D. Co-Founder, Chief Technology Officer & Director
Jeremy B. Hayden J.D. Chief Legal Officer & Corporate Secretary
Brenton Taylor Executive Vice President of Operations
Dr. Manohar K. Raheja Ph.D. Executive Vice President of Research & Development
Dr. Reay H. Brown M.D. Chief Medical Officer
Jim Rodberg Vice President of Finance & Corporate Controller
Matthew W. Link Chief Commercial Officer
Steve R. Tamayo Jr. Vice President and Chief Ethics & Compliance Officer

Latest SEC Filings

Date Type Title
Jun 05, 2025 8-K Current Report
Jun 03, 2025 4 Filing
May 30, 2025 SD Filing
May 29, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 21, 2025 4 Filing
May 15, 2025 SCHEDULE 13G/A [Amend] Filing
May 14, 2025 4 Filing
May 08, 2025 10-Q Quarterly Report